Actelion Pharmaceuticals
Australia Pty Ltd has announced
that Opsumit (macitentan), a new
endothelin receptor antagonist
(ERA) for the treatment of
pulmonary arterial hypertension
(PAH) is available on the
Pharmaceutical Benefits Scheme
(PBS) effective 01 Sep.
Opsumit is indicated for PAH
under specific conditions as either
monotherapy or in combinations
with other approved therapies.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Sep 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Sep 14
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.